Kexing Biopharm Expands European Presence Following CPHI Milan Exhibition

Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026 from October 6-8, 2026, presenting its global innovative drug pipeline, co-developed biosimilars, and products already commercialized in overseas markets. The company engaged with international drug purchasers, biotechs, and industry partners during the event.

In recent years, Kexing Biopharm has developed a mature overseas commercialization platform, securing cooperation agreements for over 30 products with multiple domestic pharmaceutical companies. Its marketing network spans approximately 70 countries and regions, with nearly 200 registration applications submitted abroad. Europe is a key market for its core product, albumin-bound paclitaxel, which is already marketed in the EU and the UK.

To enhance its local presence in Europe, Kexing Biopharm has established a subsidiary in Germany and is proceeding with plans to set up operations in France, Spain, Italy, the United Kingdom, and the Netherlands. These local entities are intended to improve responsiveness to regional customer needs and foster long-term partnerships. The company's consistent participation in CPHI events in Europe serves as a platform to deepen its regional engagement.

The company's strategic direction combines innovation and internationalization. Its displayed innovative drug pipeline, targeting areas such as cancer cachexia, ophthalmic diseases, systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD), attracted visitor attention. Kexing Biopharm leverages its 30 years of biopharmaceutical industrial experience and established manufacturing and quality management systems. Its albumin-bound paclitaxel manufacturing line holds EU GMP certification, and the product is approved in over 40 countries and regions.